Fudan University neurosurgeons receive journal award at CNS for high-ranking clinical research using VISIUS Surgical Theatre
MINNEAPOLIS, Oct. 22, 2013 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced that neurosurgeons from Huashan Hospital at Fudan University in Shanghai, China, have received a prestigious clinical journal award for their preliminary results which suggest that high-field intraoperative MRI (iMRI) within the VISIUS ® Surgical Theatre contributes to increased complete resection rates in glioma tumors.
The neurosurgical team led by Dr. Jin-song Wu was honored with the Journal of Neuro-Oncology Award at the Congress of Neurological Surgeons (CNS) Annual Meeting on October 21 in San Francisco for their presented research.
When completed, the authors are confident the prospective, parallel, randomized, triple-blind controlled trial will provide the highest level evidence to date of the value of iMRI in treating both low and high-grade gliomas. The early results reinforce that high-field iMRI-guided surgery is more effective in achieving complete resection than conventional neuronavigation-guided surgery. Other published studies on high-field iMRI have been mainly retrospective."Our preliminary results confirm some of the assumptions that intraoperative MRI enables reliable resection control to eliminate the effect of brain shift on extent of resection," Dr. Wu said. "This leads to more improved progression free survival and quality of life than using conventional neuronavigation. Although these are early results we believe they are showing trends to statistical significance and will be the highest level of iMRI evidence for glioma surgery to date." With 114 patients enrolled, complete resection rates in the iMRI group and control group were 86% and 53%, respectively. These results are backed up by volumetric analysis of extent of resection and noted as being statistically significant.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV